PRAME and cancer: To determine if these tumor antigens could be simultaneously detected and discriminated for quantitation, we used cancer cell lines known to express the three TAA: hepatoblastoma (HEP3B), which expresses BIRC5; and K562, an immortalized leukemia line that expresses WT1 and PRAME.